Teva Pharmaceutical Industries Ltd. today announced changes to its leadership team. Sven Dethlefs, Executive Vice President, North America Commercial, will leave Teva on November 17, 2023, and.
TEL AVIV, Israel & PARSIPPANY, N.J., September 28, 2023 Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced changes to its leadership team. Sven Dethlefs, Executive Vice President, North America Commercial, will leave Teva on November 17, 2023, and Christine (Chris) Fox, who most recently served as Global President, Gene Therapies at Novartis will be the new head of Teva’s U.S. Commercial Business. "On behalf of the Teva Board of Directors and our executive management team
Needham & Company LLC reiterated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have a $5.00 target price on the stock. Several other research firms have also commented on TSHA. Robert W. Baird boosted their price […]